Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 345

Sort by

Sort Order Select

Journal Articles

JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition

Vandana Chaturvedi, Nora Lakes, Minh Tran, Natalie Castillo, Michael B. Jordan

Blood (2021) 138 (12): 1034–1039.

https://doi.org/10.1182/blood.2020007930

Published: 2021

Journal Articles

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Stephen D. Smith, MD, Javier Munoz, MD MS, FACP, Don Stevens, MD, Sonali M. Smith, MD, Tatyana A. Feldman, MD, J Christine Ye, MDMSc, Sven de Vos, MD PhD, Brian T. Hess, MD, Carole B. Miller, MD, James L. Khatcheressian, MD, Matt R. Birrell, Janet M. Leeds, PhD, Gregory P. Coffey, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 3981.

https://doi.org/10.1182/blood-2019-124231

Published: 2019

Journal Articles

Persistence of Ruxolitinib Treatment in Patients with Myelofibrosis at Community Oncology Practices in the United States-Contemporary Data

Jingbo Yu, PhD, Jonathan K. Kish, PhD MPH, Dilan Paranagama, PhD, Philomena Colucci, DO, MS

Blood (2019) 134 (Supplement_1): 5385.

https://doi.org/10.1182/blood-2019-123833

Published: 2019

Journal Articles

Clinical Characteristics and Cardioavscular Events in Patients with Esential Thrombocythemia with <10% Vs. ≥10% JAK2 V617F Allele Burden

Blood (2019) 134 (Supplement_1): 4171.

https://doi.org/10.1182/blood-2019-126980

Published: 2019

Journal Articles

Dual Driver Mutant BCR-ABL1-Negative Myeloid Neoplasms: Multicenter Clinicopathologic and Genomic Analysis

Zachary D. Epstein-Peterson, MD, Joseph Tripodi, Maria E Arcila, MD, Filiz Sen, MD, Vesna Najfeld, PhD, John Mascarenhas, MD, Ronald Hoffman, MD, Rajit K. Rampal, MD, PhD

Blood (2019) 134 (Supplement_1): 4173.

https://doi.org/10.1182/blood-2019-125379

Published: 2019

Journal Articles

New Paradigms for the Mechanisms of Thrombopoietin Receptor Activation and Dysregulation By the JAK2 V617F Mutation

Stephan Wilmes, PhD, Maximillian Hafer, BSc, Tess A Stanly, Ignacio Moraga, PhD, Joni Vuorio, PhD, Chetan Poojari, PhD, Vivek Sharma, PhD, Sara Löchte, PhD, Katiuska Pulgar Prieto, BSc, Julie A Tucker, PhD, Stevan R Hubbard, PhD, K.Christopher Garcia, PhD, Ilpo Vattulainen, PhD, Ian Hitchcock, PhD, Jacob Piehler, PhD

Blood (2019) 134 (Supplement_1): 2962.

https://doi.org/10.1182/blood-2019-129234

Published: 2019

Journal Articles

Acquired Resistance to JAK Inhibitors in Calr-Mutated Myeloproliferative Neoplasms

Ken-Hong Lim, MD, Yu-Cheng Chang, MD, Yi-Hao Chiang, MD, Huan-Chau Lin, MD, Ling Huang, MSc, Wei-Ting Wang, MSc, Ying-Wen Su, MD, PhD, Ming-Chih Chang, MD, Yi-Fang Chang, MD PhD, Caleb Gon-Shen Chen, MD PhD

Blood (2019) 134 (Supplement_1): 2970.

https://doi.org/10.1182/blood-2019-124420

Published: 2019

Journal Articles

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Regina Garcia-Delgado, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, László Rejtő, Eric Jourdan, MD, Haifa Kathrin Al-Ali, MD, Andrzej Pluta, MD, Marek Hus, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Irum Khan, MD, Holger Hebart, Philipp J. Jost, MD, Sebastian Grosicki, MD PhD, Wayne M. Rothbaum, Jesse McGreivy, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2945.

https://doi.org/10.1182/blood-2019-123836

Published: 2019

Journal Articles

CD45-ADC Plus Janus Kinase (JAK) Inhibitors As Conditioning for MHC-Mismatched Murine Hematopoietic Stem Cell Transplantation Is Associated with Minimal Toxicity and Graft Versus Host Disease

Stephen P. Persaud, MD PhD, Matthew L. Cooper, PhD, Julie K. Ritchey, Michael P. Rettig, PhD, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 3200.

https://doi.org/10.1182/blood-2019-123519

Published: 2019

Journal Articles

Trial in Progress: A Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Annie Im, MD, Rodica Morariu-Zamfir, MD, Maureen Bleam, BS, Ying Yan, PhD, Steven Z. Pavletic, MD MS

Blood (2019) 134 (Supplement_1): 3277.

https://doi.org/10.1182/blood-2019-128586

Published: 2019

Journal Articles

A Biomarker Signature to Predict Complete Response to Itacitinib and Corticosteroids in Acute Graft Versus Host Disease

Michael A. Pratta, MSc, Hao Liu, PhD, Sherry Owens, PhD, Ying Yan, PhD, Michael C. Arbushites, Michael D. Howell, PhD

Blood (2019) 134 (Supplement_1): 3279.

https://doi.org/10.1182/blood-2019-124069

Published: 2019

Journal Articles

Single-Cell Analysis Based Dissection of Clonality in Myelofibrosis

Blood (2019) 134 (Supplement_1): 469.

https://doi.org/10.1182/blood-2019-123367

Published: 2019

Journal Articles

Dysregulated IL-6/GP130/JAK Signaling in Calreticulin Mutated Myeloproliferative Neoplasms (MPN)

Manjola Balliu, PhD, Laura Calabresi, PhD, Niccolò Bartalucci, PhDBSc, Laura Maggi, PhD, Francesco Annunziato, PhD, Paola Guglielmelli, MD PhD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 471.

https://doi.org/10.1182/blood-2019-123685

Published: 2019

Journal Articles

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Blood (2019) 134 (Supplement_1): 473.

https://doi.org/10.1182/blood-2019-127122

Published: 2019

Journal Articles

T-Cell Derived Interferon Gamma Directly Targets Intestinal Epithelium to Induce Stem Cell Apoptosis in GI Gvhd

Shuichiro Takashima, MD PhD, Maria L. Martin, PhD, Suze A. Jansen, Ya-Yuan Fu, PhD, Anastasiya Egorova, Chen Liu, MD PhD, Richard Kolesnick, MD, Caroline A. Lindemans, MD, Alan M. Hanash, MD PhD

Blood (2019) 134 (Supplement_1): 585.

https://doi.org/10.1182/blood-2019-130811

Published: 2019

Journal Articles

Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis

Blood (2019) 134 (Supplement_1): 555.

https://doi.org/10.1182/blood-2019-130046

Published: 2019

Journal Articles

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

Blood (2019) 134 (Supplement_1): 558.

https://doi.org/10.1182/blood-2019-131217

Published: 2019

Journal Articles

Azacytidine Inhibits Megakaryopoiesis Via the Induction of Immunogenic RNA Species and Activation of Type-I Interferon Signaling

Ujunwa Cynthia Okoye-Okafor, MS,PhD, Komal Kumar Javarappa, PhD, Dimitrios Tsallos, BSc(Hons),MSc, Joseph J Saad, MSc, BSc, Lumie Benard, Victor Thiruthuvanathan, M.S, Sally Cole, Madhuri Tatiparthy, M.S., Stephen Ruiz, B.Sc, Stefanie DeFronzo, Celine Pallaud, PhD, Pedro Marques Ramos, PhD, Amit Verma, MBBS, Aditi Shastri, MD, Caroline A Heckman, PhD, Britta Will, PhD

Blood (2019) 134 (Supplement_1): 1280.

https://doi.org/10.1182/blood-2019-131461

Published: 2019

Journal Articles

Disease Progression, Hospital Readmissions, and Clinical Outcomes of Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: A Multicenter Chart Review

Jingbo Yu, PhD, Becky Hanna, Dilan Paranagama, PhD, Jackson Tang, Ahmad Naim, MD, John P Galvin, MDMS,MPH

Blood (2019) 134 (Supplement_1): 1994.

https://doi.org/10.1182/blood-2019-127492

Published: 2019

Journal Articles

Overall Survival in Patients with Myelofibrosis Who Have Discontinued Ruxolitinib: A Literature Review

Derek Tang, PhD BSPharm, Ankush Taneja, Preety Rajora, Indeg Sly, Niall James Davison

Blood (2019) 134 (Supplement_1): 3457.

https://doi.org/10.1182/blood-2019-122904

Published: 2019

NARROW

JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Persistence of Ruxolitinib Treatment in Patients with Myelofibrosis at Community Oncology Practices in the United States-Contemporary Data

Clinical Characteristics and Cardioavscular Events in Patients with Esential Thrombocythemia with <10% Vs. ≥10% JAK2 V617F Allele Burden

Dual Driver Mutant BCR-ABL1-Negative Myeloid Neoplasms: Multicenter Clinicopathologic and Genomic Analysis

New Paradigms for the Mechanisms of Thrombopoietin Receptor Activation and Dysregulation By the JAK2 V617F Mutation

Acquired Resistance to JAK Inhibitors in Calr-Mutated Myeloproliferative Neoplasms

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

CD45-ADC Plus Janus Kinase (JAK) Inhibitors As Conditioning for MHC-Mismatched Murine Hematopoietic Stem Cell Transplantation Is Associated with Minimal Toxicity and Graft Versus Host Disease

Trial in Progress: A Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

A Biomarker Signature to Predict Complete Response to Itacitinib and Corticosteroids in Acute Graft Versus Host Disease

Single-Cell Analysis Based Dissection of Clonality in Myelofibrosis

Dysregulated IL-6/GP130/JAK Signaling in Calreticulin Mutated Myeloproliferative Neoplasms (MPN)

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

T-Cell Derived Interferon Gamma Directly Targets Intestinal Epithelium to Induce Stem Cell Apoptosis in GI Gvhd

Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

Azacytidine Inhibits Megakaryopoiesis Via the Induction of Immunogenic RNA Species and Activation of Type-I Interferon Signaling

Disease Progression, Hospital Readmissions, and Clinical Outcomes of Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: A Multicenter Chart Review

Overall Survival in Patients with Myelofibrosis Who Have Discontinued Ruxolitinib: A Literature Review

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only